GI Innovation accelerates development of next-generation food allergy treatment with AI precision design; files patent application for GI-308

[Financial News] Artificial intelligence (AI) is also speeding up the development of new food allergy drugs. The approach uses AI to precisely design antibody structures and identify new therapeutic candidates.
GI Innovation said on the 12th that it had filed a patent application for GI-308, a next-generation food allergy treatment candidate developed using AI-based protein structure modeling technology.
GI-308 was created by applying the company's advanced AI-based precision antibody design technology to the discovery of new candidates. The company had previously applied the technology to GI-305, its existing allergy treatment pipeline, to optimize the candidate and filed two related patent applications. With this filing, the company's food allergy treatment patent portfolio has expanded to include GI-308, following GI-305 and GI-307. The strategy is to raise patent barriers to secure a competitive edge in the global market.
GI-308 was designed to differ from GI-305 in structure and mechanism of action. Using AI-based protein structure modeling and antibody engineering technologies, the company precisely analyzed how a nanobody (VHH) targeting IL-4Rα and an antibody against an undisclosed target each bind to their respective targets. Based on this analysis, it optimized the structure of each antibody component.
Food allergy is a condition caused by the immune system overreacting to certain foods and can lead to life-threatening anaphylaxis in severe cases. Current approaches include avoiding trigger foods, administering epinephrine in emergencies, and using antibody therapies targeting Immunoglobulin E (IgE). However, effects take time to appear, responses vary from patient to patient, and long-term benefits are difficult to achieve, leaving a significant unmet medical need.
The company aims to use GI-308 to develop a treatment that acts faster than existing treatments and provides longer-lasting protection.
CEO Jang Myeong-ho said, "GI-308 is a next-generation food allergy treatment candidate that combines the company's accumulated expertise in immunological disease research with AI-based structural design technology. We will demonstrate its differentiated competitive strengths—rapid onset of drug action and sustained suppression of allergic reactions—and continue expanding our patent portfolio to raise barriers to entry in the global market and build our competitiveness as an innovative new drug."


[email protected] Jeong Myeong-jin, Medical Correspondent Reporter